GEOapplication/xmlftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE322nnn/GSE322742/suppl/filelist.txtftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE322nnn/GSE322742/suppl/GSE322742_RAW.tarftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE322nnn/GSE322742/primaryOK200TranscriptomicsHomo sapiensExpression profiling by high throughput sequencinghttps://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE322742GEOGSEfalseTranscriptional profiling of sorafenib-resistant and parental sensitive HepG2 and Huh7 hepatocellular carcinoma cellsHepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide, and acquired resistance to sorafenib—the first-line targeted therapy for advanced HCC—remains a major clinical challenge. To investigate the molecular mechanisms underlying sorafenib resistance in HCC, we established sorafenib-resistant sublines of HepG2 and Huh7 cells through continuous exposure to increasing concentrations of sorafenib. We then performed RNA-seq analysis comparing these resistant sublines with their parental sensitive counterparts. Differential gene expression analysis revealed distinct transcriptional signatures associated with sorafenib resistance. Our findings provide a comprehensive transcriptomic resource for understanding sorafenib resistance mechanisms and identify potential candidate genes that may serve as biomarkers or therapeutic targets for overcoming drug resistance in HCC.2026/06/10GSE322742GSM9557560GSM9557554GSM9557553GSM9557556GSM9557555GSM9557558GSM9557557GSM955755924676322742Homo sapiens[42026022]